
|Videos|March 17, 2022
Dr. Shore encourages clinicians to implement hereditary cancer risk assessments in their practices
Author(s)Urology Times staff
“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.
Advertisement
In this video, Neal D. Shore, MD, FACS, discusses the takeaways of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5





